Reporter Sept 21 2012

Target acquired for aggressive tumor

New therapeutic target for angiosarcoma – an aggressive, highly fatal tumor of the blood vessels – identified.

Cell entry ports for cold virus

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.

VU, Bristol-Myers to collaborate on Parkinson’s therapies

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

HER2 may impact lung cancer therapy

A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies.

Wellons named chief of Pediatric Neurosurgery

The Department of Neurological Surgery has recruited John “Jay” Wellons III, M.D., MSPH, to serve as chief of Pediatric Neurosurgery.

Mchaourab to lead Chemical and Physical Biology program

Hassane Mchaourab, Ph.D., professor of Molecular Physiology & Biophysics, Physics and Chemistry, has been named the new director of the Ph.D.-granting Chemical and Physical Biology (CPB) program at Vanderbilt University.

1 2